Skip to main content

Apidra FDA Approval History

FDA Approved: Yes (First approved April 16, 2004)
Brand name: Apidra
Generic name: insulin glulisine
Dosage form: Injection
Company: Aventis Pharmaceuticals Inc.
Treatment for: Diabetes, Type 1, Diabetes, Type 2

Apidra (insulin glulisine) is a rapid-acting recombinant DNA human insulin analogue used for the control of hyperglycemia in patients with diabetes mellitus.

Development timeline for Apidra

Feb 26, 2009Approval FDA Approves Apidra SoloSTAR - a Prefilled Disposable Insulin Pen
Oct 29, 2008Approval FDA Approves Rapid-Acting Insulin Apidra for Treatment of Children with Diabetes
Jun 15, 2007Approval FDA Approves New Route of Administration for Rapid-Acting Apidra Providing an Additional Treatment Option for Hospitalized Diabetes Patients with High Blood Sugar Levels
Apr 16, 2004Approval Apidra Aventis Pharmaceuticals Inc. - Treatment for Diabetes Mellitus

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.